BSECompany Update4d ago · 16 Oct 2026, 02:59 pm
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
AstraZeneca Pharma India Ltd · 506820
✦ AI SummaryESG
AstraZeneca Pharma India Ltd has been assigned an ESG rating of 73 by NSE Sustainability Ratings and Analytics Limited for financial year 2025-26.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Credit Rating
Attachments (1)
📄pdf
Download →
d3181d29-8b79-46fc-a077-058a75f62007.pdf
View document text
October 16, 2026
The Manager – Listing
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai – 400001
The Manager – Listing
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (E),
Mumbai – 400051
Dear Sir/Madam,
Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 – Disclosure of ESG Rating
With reference to the captioned subject, please note that NSE Sustainability Ratings and Analytics
Limited has assigned an Environmental, Social and Governance (“ESG”) rating of 73 for the
Company for financial year 2025-26.
Please note that the Company has not engaged NSE Sustainability Ratings and Analytics Limited.
NSE Sustainability Ratings and Analytics Limited has independently prepared their reporting based
on publicly available information of the Company.
Kindly take the above information on record.
Thanking you,
For AstraZeneca Pharma India Limited
Tanya Sanish
Company Secretary & Compliance Officer
ACS No.: A25784